AI assistant
TransMedics Group, Inc. — Director's Dealing 2025
Oct 31, 2025
31201_dirs_2025-10-31_834fd5e6-e785-469a-be4d-0c49d548f320.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2025-10-29
Reporting Person: Basile Edward M (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-10-29 | Common Stock | M | 4142 | $0.70 | Acquired | 7008 | Direct |
| 2025-10-29 | Common Stock | S | 4142 | $130.45 | Disposed | 2866 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-10-29 | Stock Option (Right to Buy) | $0.70 | M | 4142 | Disposed | 2026-02-16 | Common Stock (4142) | Direct |
Footnotes
F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on November 6, 2024.
F2: The option is fully vested.
F3: The Stock Option reported herein as being disposed of is an option to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.